SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Diaz-Buxo JA, Lowrie EG, Lew NL, Zhang HY, Zhu XF, Lazarus JM. Associates of mortality among peritoneal dialysis patients with special reference to peritoneal transport rates and solute clearance. Am. J. Kidney Dis. 1999; 33: 52334.
  • 2
    Termorshuizen F, Korevaar JC, Dekker FW et al. The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: An analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) -2. Am. J. Kidney Dis. 2003; 41: 1293302.
  • 3
    Szeto CC, Wong T, Leung C et al. Importance of dialysis adequacy in mortality and morbidity of Chinese CAPD patients. Kidney Int. 2000; 58: 400407.
  • 4
    Rocco M, Soucie JM, Pastan S, Mcclellan WM. Peritoneal dialysis adequacy and risk of death. Kidney Int. 2000; 58: 44657.
  • 5
    Churchill DN, Taylor DW, Keshaviah PR for the Canusa Peritoneal Dialysis Study Group. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: Association with clinical outcomes. J. Am. Soc. Nephrol. 1996; 7: 198207.
  • 6
    Bargman JM, Thorpe KE, Churchill DN for the Canusa Peritoneal Dialysis Study Group. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis; A reanalysis of the CANUSA study. J. Am. Soc. Nephrol. 2001; 12: 215862.
  • 7
    Shemin D, Bostom AG, Laliberty P, Dworkin LD. Residual renal function and mortality risk in hemodialysis patients. Am. J. Kidney Dis. 2001; 38: 8590.
  • 8
    Termorshuizen F, Dekker FW, Van Manen JG et al. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: An analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J. Am. Soc. Nephrol. 2004; 15: 106170.
  • 9
    Eknoyan G, Beck GJ, Cheung AK et al. for the Hemodialysis (HEMO) Study Group. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N. Engl. J. Med. 2002; 347: 201019.
  • 10
    Bammens B, Evenpoel P, Verbeke K, Vanrenterghem Y. Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int. 2003; 64: 223843.
  • 11
    Bammens B, Evenpoel P, Verbeke K, Vanrenterghem Y. Time profiles of peritoneal and renal clearances of different uremic solutes in incident peritoneal dialysis patients. Am. J. Kidney Dis. 2005; 46: 51219.
  • 12
    Mccarthy JT, Williams AW, Johnson WJ. Serum beta 2-microglobulin concentration in dialysis patients: Importance of intrinsic renal function. J. Lab. Clin. Med. 1994; 123: 495505.
  • 13
    Lopez-Menchero R, Miguel A, Garcia-Ramon R, Perez-Contreras J, Girbes V. Importance of residual renal function in continuous ambulatory peritoneal dialysis: Its influence on different parameters of renal replacement treatment. Nephron 1999; 83: 21925.
  • 14
    Mistry CD, O'Donoghue DJ, Nelson R, Gokal R, Ballardie FW. Kinetic and clinical studies of beta 2 microglobulin in continuous peritoneal dialysis: Influence of renal and enhanced peritoneal clearances using glucose polymer. Nephrol. Dial. Transplant. 1990; 5: 51319.
  • 15
    Catizone L, Cocchi R, Fusaroli M, Zucchelli P. Relationship between plasma beta-2 microglobulin and residual diuresis and continuous ambulatory peritoneal dialysis and hemodialysis patients. Perit. Dial. Int. 1993; 13 (Suppl. 2): S5236.
  • 16
    Montenegro J, Martinez I, Saracho R, Gonzalez R. Beta 2 microglobulin in CAPD. Adv. Perit. Dial. 1992; 8: 36972.
  • 17
    Amici G, Virga G, Da Rin G et al. Serum beta-2-microglobulin level and residual renal function in peritoneal dialysis. Nephron 1993; 65: 46971.
  • 18
    Ates K, Nergizoglu G, Keven K et al. Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. Kidney Int. 2001; 60: 76776.
  • 19
    Konings CJ, Kooman JP, Schonck M et al. Fluid status in CAPD patients is related to peritoneal transport and residual renal function: Evidence from a longitudinal study. Nephrol. Dial. Transplant. 2003; 18: 797803.
  • 20
    Menon MK, Naimark DM, Bargman JM, Vas SI, Oreopoulos DG. Long-term blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function. Nephrol. Dial. Transplant. 2001; 16: 220713.
  • 21
    Wang AY, Wang M, Woo J et al. A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients. Kidney Int. 2002; 62: 63947.
  • 22
    Wang AY, Wang M, Woo J et al. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J. Am. Soc. Nephrol. 2004; 15: 218694.
  • 23
    Wang AY, Lam CW, Wang M et al. Circulating soluble vascular cell adhesion molecule 1: Relationships with residual renal function, cardiac hypertrophy, and outcome of peritoneal dialysis patients. Am. J. Kidney Dis. 2005; 45: 71529.
  • 24
    Chung SH, Heimburger O, Stenvinkel P, Qureshi AR, Lindholm B. Association between residual renal function, inflammation and patient survival in new peritoneal dialysis patients. Nephrol. Dial. Transplant. 2003; 18: 59097.
  • 25
    Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? Kidney Int. 2001; 59: 40714.
  • 26
    Aguilera A, Codoceo R, Bajo MA et al. Helicobacter pylori infection: A new cause of anorexia in peritoneal dialysis patients. Perit. Dial. Int. 2001; 21 (Suppl. 3): S1526.
  • 27
    Wang AY, Sea MM, Ip R et al. Independent effects of residual renal function and dialysis adequacy on actual dietary protein, calorie, and other nutrient intake in patients on continuous ambulatory peritoneal dialysis. J. Am. Soc. Nephrol. 2001; 12: 245057.
  • 28
    Wang AY, Sea MM, Ip R et al. Independent effects of residual renal function and dialysis adequacy on dietary micronutrient intakes in patients receiving continuous ambulatory peritoneal dialysis. Am. J. Clin. Nutr. 2002; 76: 56976.
  • 29
    Caravaca F, Arrobas M, Dominguez C. Influence of residual renal function on dietary protein and caloric intake in patients on incremental peritoneal dialysis. Perit. Dial. Int. 1999; 19: 35056.
  • 30
    Shemin D, Bostom AG, Lambert C, Hill C, Kitsen J, Kliger AS. Residual renal function in a large cohort of peritoneal dialysis patients: Change over time, impact on mortality and nutrition. Perit. Dial. Int. 2000; 20: 43944.
  • 31
    Page DE, Knoll GA, Cheung V. The relationship between residual renal function, protein catabolic rate and phosphate and magnesium levels in peritoneal dialysis patients. Adv. Perit. Dial. 2002; 18: 18991.
  • 32
    Merkus MP, Jager KJ, Dekker FW et al. Quality of life in patients on chronic dialysis: Self-assessment 3 months after the start of treatment. Am. J. Kidney Dis. 1997; 24: 58492.
  • 33
    Merkus MP, Jager KJ, Dekker FW et al. Physical symptoms and quality of life in patients on chronic dialysis: Results of The Netherlands Cooperative Study on Adequacy of Dialysis (NECOSAD). Nephrol. Dial. Transplant. 1999; 14: 116370.
  • 34
    Dixit MP, Cabansag MR, Piscitelli J, Greifer I, Silverstein DM. Serum beta-2- microglobulin and immunoglobulin levels in young hemodialysis patients. Pediatr. Nephrol. 1999; 13: 13942.
  • 35
    Pickett TM, Cruickshank A, Greenwoood RN, Taube D, Davenport A, Farrington K. Membrane flux not biocompatibility determines beta-2-microglobulin levels in hemodialysis patients. Blood Purif. 2002; 20: 1616.
  • 36
    Suda T, Hiroshige K, Ohta T et al. The contribution of residual renal function to overall nutritional status in chronic haemodialysis patients. Nephrol. Dial. Transplant. 2000; 15: 396401.
  • 37
    Erkan E, Moritz M, Kaskel F. Impact of residual renal function in children on hemodialysis. Pediatr. Nephrol. 2001; 16: 85861.
  • 38
    Morduchowicz G, Winkler J, Zabludowski JR, Boner G. Effects of residual renal function in haemodialysis patients. Int. Urol. Nephrol. 1994; 26: 12531.
  • 39
    Ravid M, Lang R, Robson M. The importance of daily urine Volume and residual renal function in patients treated by chronic hemodialysis. Dial. Transplant. 1980; 9: 7635.
  • 40
    Hartmann J, Fricke H, Schiffl H. Biocompatible membranes preserve residual renal function in patients undergoing regular hemodialysis. Am. J. Kidney Dis. 1997; 30: 36673.
  • 41
    Canaud B, Chenine L, Leray-Moragues H, Wiesen H, Tetta C. Residual renal function and dialysis modality: Is it really beneficial to preserve residual renal function in dialysis patients? Nephrology 2006; 11: 2926.
  • 42
    Gunal AI, Kirciman E, Guler M, Yavuzkir M, Celiker H. Should the preservation of residual renal function cost Volume overload and its consequence left ventricular hypertrophy in new hemodialysis patients? Ren. Fail. 2004; 26: 4059.
  • 43
    Rottembourg J, Issad B, Gallego JL et al. Evolution of residual renal function in patients undergoing maintenance hemodialysis or continuous peritoneal dialysis. Proc. Eur. Dial. Transplant. Assoc. 1983; 19: 397403.
  • 44
    Cancarini GC, Brunori G, Camerini C, Brasa S, Manili L, Maiorca R. Renal function recovery and maintenance of residual diuresis in CAPD and hemodialysis. Perit. Dial. Bull. 1986; 6: 779.
  • 45
    Lysaght MJ, Vonesh EF, Gotch F et al. The influence of dialysis treatment modality on decline of remaining renal function. ASAIO. Trans. 1991; 37: 598604.
  • 46
    Moist LM, Port FK, Orzol SM et al. Predictors of loss of residual renal function among new dialysis patients. J. Am. Soc. Nephrol. 2000; 11: 55664.
  • 47
    Misra M, Vonesh E, Van Stone JC, Moore HL, Prowant B, Nolph KD. Effect of cause and time of dropout on the residual GFR: A comparative analysis of the decline of GFR on dialysis. Kidney Int. 2001; 59: 75463.
  • 48
    Lang SM, Bergner A, Topfer M et al. Preservation of residual renal function in dialysis patients: Effects of dialysis-technique-related factors. Perit. Dial. Int. 2001; 21: 527.
  • 49
    Jansen MA, Hart AA, Korevaar JC et al. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int. 2002; 62: 104653.
  • 50
    Mckane W, Chandna SM, Tattersall JE, Greenwook RN, Farrington K. Identical decline of residual renal function in high-flux biocompatible hemodialysis and CAPD. Kidney Int. 2002; 61: 25665.
  • 51
    Hakim RM, Pontzer MA, Tilton D, Lazarus JM, Gottlieb MN. Effects of acetate and bicarbonate dialysate in stable chronic dialysis patients. Kidney Int. 1985; 28: 53540.
  • 52
    La Greca G, Feriani M, Bragantini L, Petrosino L, Santoro A, Altieri P. Effects of acetate and bicarbonate dialysate on vascular stability: A prospective multicentre study. Int. J. Artif. Organs 1987; 10: 15762.
  • 53
    Caramelo C, Alcazar R, Gallar P et al. Choice of dialysis membrane does not influence the outcome of residual renal function in haemodialysis patients. Nephrol. Dial. Transplant. 1994; 9: 6757.
  • 54
    Van Stone JC. The effect of dialyser membrane and etiology of kidney disease on the preservation of residual renal function in chronic hemodialysis patients. ASAIO. J. 1995; 41: 71316.
  • 55
    Hakim RM, Wingard RL, Husni L, Parker RA, Parker TF III. The effect of membrane biocompatibility on plasma β2-microglobulin levels in chronic hemodialysis patients. J. Am. Soc. Nephrol. 1996; 7: 4728.
  • 56
    McCarthy JT, Jenson BM, Squillace DP, Williams AW. Improved preservation of residual renal function in patients undergoing chronic hemodialysis using polysulfone dialysers. Am. J. Kidney Dis. 1997; 29: 57683.
  • 57
    Stannat S, Bahlmann J, Kiessling D, Koch KM, Deicher H, Peter HH. Complement activation during hemodialysis. Comparison of polysulfone and cuprophan membranes. Contrib. Nephrol. 1985; 46: 1028.
  • 58
    Woffindin C, Hoenich NA. Blood–membrane interactions during haemodialysis with cellulose and synthetic membranes. Biomaterials 1988; 9: 537.
  • 59
    Schiffl H, Lang SM, Fischer R. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol. Dial. Transplant. 2002; 17: 181418.
  • 60
    Van Olden RW, Krediet RT, Struijk DG, Arisz L. Measurement of residual renal function in patients treated with continuous ambulatory peritoneal dialysis. J. Am. Soc. Nephrol. 1996; 7: 74550.
  • 61
    Van Olden RW, Van Acker AC, Koomen GCM, Krediet RT, Arisz L. Time course of inulin and creatinine clearance in the interval between two haemodialysis treatments. Nephrol. Dial. Transplant. 1995; 10: 227480.
  • 62
    Milutinovic J, Cutler RE, Hoover P, Meijsen B, Scribner BH. Measurement of residual glomerular filtration rate in the patient receiving repetitive hemodialysis. Kidney Int. 1975; 8: 18590.
  • 63
    Hemodialysis Adequacy 2006 Workgroup. KDOQI Clinical practice guidelines for hemodialysis adequacy, Update 2006. Am. J. Kidney Dis. 2006; 48 (Suppl. 1): S290.
  • 64
    European Best Practice Guidelines Working Group. European Best Practice Guidelines for Haemodialysis (Part 1). Nephrol. Dial. Transplant. 2002; 17 (Suppl. 7): 1111.
  • 65
    Depner TA. Haemodialysis adequacy: Basic essentials and practical points for the nephrologists in training. Hemodial. Int. 2005; 9: 24154.
  • 66
    Gotch FA. The current place of urea kinetic modeling with respect to different dialysis modalities. Nephrol. Dial. Transplant. 1998; 13 (Suppl. 6): S1014.
  • 67
    Singhal MK, Bhaskaran S, Vidgen E, Bargman JM, Vas SI, Oreopoulos DG. Rate of decline of residual renal function in patients on continuous peritoneal dialysis and factors affecting it. Perit. Dial. Int. 2000; 20: 42938.
  • 68
    Shin SK, Noh H, Kang SW et al. Risk factors influencing the decline of residual renal function in continuous ambulatory peritoneal dialysis patients. Perit. Dial. Int. 1999; 19: 13842.
  • 69
    Holley JL, Aslam N, Bernardini J, Fried L, Piraino B. The influence of demographic factors and modality on loss of residual renal function in incident peritoneal dialysis patients. Perit. Dial. Int. 2001; 21: 3025.
  • 70
    Hidaka H, Nakao T. Preservation of residual renal function and factors affecting its decline in patients on peritoneal dialysis. Nephrology (Carlton) 2003; 8: 18491.
  • 71
    Johnson DW, Mudge DW, Sturtevant JM et al. Predictors of decline of residual renal function in new peritoneal dialysis patients. Perit. Dial. Int. 2003; 23: 27683.
  • 72
    Shemin D, Maaz D, St Pierre D, Kahn SI, Chazan JA. Effect of aminoglycoside use on residual renal function in peritoneal dialysis patients. Am. J. Kidney Dis. 1999; 34: 1420.
  • 73
    Hufnagel G, Michel C, Queffeulou G, Skhiri H, Damieri H, Mignon F. The influence of automated peritoneal dialysis on the decrease in residual renal function. Nephrol. Dial. Transplant. 1999; 14: 12248.
  • 74
    Moranne O, Willoteaux S, Pagniez D, Dequiedt P, Boulanger E. Effect of iodinated contrast agents on residual renal function in PD patients. Nephrol. Dial. Transplant. 2006; 21: 104045.
  • 75
    Iest GC, Vanholder RC, Ringoir SM. Loss of residual renal function in patients on regular haemodialysis. Int. J. Artif. Organs 1989; 12: 15964.
  • 76
    Van Olden RW, Guchelaar HJ, Strujik DG, Krediet RT, Arisz L. Acute effects of high-dose frusemide on residual renal function in CAPD patients. Perit. Dial. Int. 2003; 23: 33947.
  • 77
    Medcalf JF, Harris KPG, Walls J. Role of diuretics in the preservation of renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int. 2001; 59: 112833.
  • 78
    Li PK, Chow KM, Wong YH, Leung CB, Szeto CC. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. Ann. Int. Med. 2003; 139: 10512.
  • 79
    Suzuki H, Kanno Y, Sugahara S, Okada H, Nakamoto H. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am. J. Kidney Dis. 2004; 43: 105664.